To study the role of the HRAS cancer target and cisplatin resistance in bladder cancer, a T24 cell line with mutant HRAS (G12V, ATCC), expressing the highest level of HRAS (Figure 1D), and displaying the best sensitivity to pterostilbene was chosen for further experiments. Here, HRAS is linked to urinary bladder cancer.